Popular search terms:
CSL's Financial Results
CSL's Half Year financial results were announced on Wednesday, 12th February 2020. Please click the link below to view our historic Full Year and Half Year Financial Results.
More InformationSearch Results
143 results found-
Financial Results and Information | CSL Limited
CSL's exceptionally strong performance is a result of the focused execution of our strategy. Learn more.
https://www.csl.com/investors/financial-results-and-information -
For immediate release 12 February 2020
The financial results of the subsidiaries are prepared using consistent accounting policies and for the same reporting period as the parent company.
https://medialib.csl.com/-/media/shared/documents/results/2020-hy-asx.pdf -
CSL Limited ABN: 99 051 588 348 ASX Full-year information 30 June 2019 Lodged with the ASX under Listing Rule 4.3A.
The financial results of the subsidiaries are prepared using consistent accounting policies and for the same reporting period as the parent company.
https://medialib.csl.com/-/media/shared/documents/results/2019-fy-asx.pdf -
Driven by Our Promise TM
In addition to delivering solid improve the efficiency of our business and the way in which financial results, we made significant contributions in the we help patients.
https://www.csl.com/-/media/csl/documents/annual-report-docs/csl-ltd-annual-report-2019-full.pdf -
CSL Limited ABN: 99 051 588 348
As a consequence, we completed a major review of CSL's remuneration framework The remuneration outcomes in 2018 reflect CSL's outstanding financial results and taking into consideration shareholder and stakeholder feedback, market expectations achievements across CSL's operational and development activities.
https://medialib.csl.com/-/media/shared/documents/results/2018-fy-asx.pdf -
4D
The financial results of the subsidiaries are prepared using consistent accounting policies and the same reporting period as the parent company.
https://www.csl.com/-/media/shared/documents/results/2019-hy-asx.pdf -
CSL Limited Paul Perreault, CEO and MD 2020 Half Year Results David Lamont, CFO 12 February 2020 LEGAL NOTICE Forward looking st...
CSL Limited Paul Perreault, CEO and MD 2020 Half Year Results David Lamont, CFO 12 February 2020 LEGAL NOTICE Forward looking statements The materials in this presentation speak only as of the date of these materials, and include forward looking statements about CSL Limited and its related bodies corporate (CSL) financial results and estimates, business prospects and products in research, all of which involve substantial risks and uncertainties, many of which are outside the control of, and are unknown to, CSL.
https://medialib.csl.com/-/media/shared/documents/results/2020-hy-analyst.pdf -
CSL Limited is a global biotherapy industry leader.
CSL Limited is a global biotechnology manufacturer that researches, develops, and markets products to treat and prevent rare and serious diseases. Learn more.
https://www.csl.com/ -
ASX Full-year information 30 June 2017
The revenues and expenses of the prior CSL Intellectual Property segment have been combined with the financial results of the CSL Behring segment.
https://medialib.csl.com/-/media/shared/documents/results/2017-fy-asx.pdf -
CSL Limited 45 Poplar Rd, Parkville Victoria 3052 Australia
As a result, our financial results may be adversely affected by fluctuations in foreign currency exchange rates or foreign currency exchange controls.
https://www.csl.com/-/media/csl/documents/february-2019-csl-prospectus_final.pdf